France Retinal Vein Occlusion Market Size & Outlook, 2025-2033
France Retinal Vein Occlusion Market Insights
- As highlighted in Reed Intelligence analysis, the France Retinal Vein Occlusion Market, worth USD 106.97 Million in 2024, is forecasted to achieve USD 179.92 Million by 2033.
- The France market is anticipated to grow at a CAGR of 5.96% during the period 2026–2033.
- By 2024, Branch Retinal Artery Occlusion represented the largest share of the By Type market size.
- Central Retinal Vein Occlusion is expected to remain the key growth driver within By Type, registering the fastest CAGR during the forecast period.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- France accounted for 4.35% of the global Retinal Vein Occlusion Market size in 2024.
- By 2033, United States is expected to remain the top global market in terms of size.
- Within Europe, Germany is forecasted to dominate the regional Retinal Vein Occlusion Market size by 2033.
- Russia will be the fastest-growing market in Europe, projected to achieve USD 85.09 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 106.97 Million |
| Market Size In 2033 | USD 179.92 Million |
| Largest segment | Branch Retinal Artery Occlusion |
| Units | Revenue in USD Million |
| CAGR | 5.96% (2025-2033) |
| Segmnetation Covered | |
| By Type |
|
| By Condition |
|
| By Diagnosis |
|
| By Treatment |
|
| By End-User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
France Retinal Vein Occlusion Market By Type 2025-2033 (USD Million)
| By Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Branch Retinal Artery Occlusion | XX.x | XX.x | XX.x | 64.56 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Central Retinal Vein Occlusion | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Retinal Vein Occlusion Market By Condition 2025-2033 (USD Million)
| By Condition | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Ischemic | XX.x | XX.x | XX.x | 69.35 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ischemic | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Retinal Vein Occlusion Market By Diagnosis 2025-2033 (USD Million)
| By Diagnosis | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Optical Coherence Tomography (OCT) | XX.x | XX.x | XX.x | 43.09 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Fundoscopic Examination | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Fluorescein Angiography | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Retinal Vein Occlusion Market By Treatment 2025-2033 (USD Million)
| By Treatment | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Vascular Endothelial Growth Factor | XX.x | XX.x | XX.x | 51.46 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Corticosteroid Drugs | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Laser Retinal Photocoagulation | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Retinal Vein Occlusion Market By End-User 2025-2033 (USD Million)
| By End-User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 50.99 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Research and Academics Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
